Serum Resistin as a Biomarker in Nonalcoholic Fatty Liver Disease: Is This a Road to be Taken?

Patoulias, Dimitrios

doi:10.14218/jcth.2021.00236

Cited by 1 publication

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…158 A recent meta-analysis reported that serum resistin levels were increased in NAFLD as compared to healthy controls and could help to monitor fibrosis in NAFLD patients while lower levels were reported in NASH patients. 80,159 Resistin was shown to play vital role in in vitro models of obesity induced liver cancer and may act as a potential target to reverse the impact of obesity on progression of hepatic cancers. 160 High serum resistin levels was found to be an independent risk factor for the development of HCV associated HCC and allowed early identification of patients with cirrhosis having substantial increased risks of HCC.…”

Section: Resistinmentioning

confidence: 99%

“…Serum resistin levels exhibit an inverse relationship with liver fibrosis stage in NASH patients 158 . A recent meta‐analysis reported that serum resistin levels were increased in NAFLD as compared to healthy controls and could help to monitor fibrosis in NAFLD patients while lower levels were reported in NASH patients 80,159 . Resistin was shown to play vital role in in vitro models of obesity induced liver cancer and may act as a potential target to reverse the impact of obesity on progression of hepatic cancers 160 .…”

Section: Adipokinesmentioning

confidence: 99%

See 1 more Smart Citation

Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma

Vachher

Bansal

Kumar

et al. 2022

J of Cellular Biochemistry

View full text Add to dashboard Cite

Globally the incidence of hepatocellular carcinoma (HCC) is on an upsurge. Evidence is accumulating that liver disorders like nonalcoholic fatty liver disease (NAFLD) and its more progressive form nonalcoholic steatohepatitis (NASH) are associated with increased risk of developing HCC. NAFLD has a prevalence of about 25% and 50%–90% in obese population. With the growing burden of obesity epidemic worldwide, HCC presents a major healthcare burden. While cirrhosis is one of the major risk factors of HCC, available literature suggests that NAFLD/NASH associated HCC also develops in minimum or noncirrhotic livers. Therefore, there is an urgent need to understand the pathogenesis and risk factors associated with NAFLD and NASH related HCC that would help in early diagnosis and favorable prognosis of HCC secondary to NAFLD. Adipokines, hepatokines and myokines are factors secreted by adipocytes, hepatocytes and myocytes, respectively, playing essential roles in cellular homeostasis, energy balance and metabolism with autocrine, paracrine and endocrine effects. In this review, we endeavor to focus on the role of these organokines in the pathogenesis of NAFLD/NASH and its progression to HCC to augment the understanding of the factors stimulating hepatocytes to acquire a malignant phenotype. This shall aid in the development of novel therapeutic strategies and tools for early diagnosis of NAFLD/NASH and HCC.

show abstract

Section: Resistinmentioning

confidence: 99%